Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Developing & Evaluating COVID-19 Treatment Strategies

A masked researcher looks through a microscope in a laboratory.

NICHD supports and conducts research to identify effective ways to diagnose and treat COVID-19.

One study led by NICHD researchers found that an experimental drug called TEMPOL could be a promising treatment for COVID-19. The team discovered TEMPOL’s effectiveness by evaluating a more basic question on how SARS-CoV-2 uses its RNA replicase, an enzyme that allows the virus to replicate its genome and make copies of itself once inside a cell. Their findings indicate that the SARS-CoV-2 RNA replicase requires two iron-sulfur clusters to function optimally. Because TEMPOL can degrade iron-sulfur clusters, the researchers tested the drug and found that it can prevent SARS-CoV-2 from making copies of itself. The team’s next steps are conducting animal studies and seeking opportunities to evaluate TEMPOL in a clinical study of COVID-19.

Another NICHD-supported study investigated how a certain segment of the SARS-CoV-2 spike protein helps the virus infect human cells. The researchers found three sites on the spike protein that are involved in a process called S-acylation, which appears critical for the virus’ ability to infect cells. The findings suggest that blocking S-acylation could serve as a potential strategy for developing COVID-19 treatments. The team also developed an experimental system that will make it easier and quicker to investigate the detailed mechanisms of SARS-CoV-2 spike S-acylation and to identify molecules that could block this process.

In addition, NICHD-supported researchers are investigating treatments for specific groups, such as pregnant women and children. Pregnant women are at higher risk for severe illness from COVID-19, but information about treatments for pregnant women is lacking. One NICHD- and NIH-supported study is evaluating the effects on pregnancy of a drug called remdesivir, which is approved by the U.S. Food and Drug Administration for the treatment of COVID-19 in adults and children over age 12 years. Studies like these will give healthcare providers scientific evidence to make more informed decisions when treating pregnant patients.

The outcomes of NICHD’s COVID-19 research will help to inform healthcare practices and provide a foundation for future research.